Since 2006, YPrime has helped biopharmaceutical organizations expedite and improve the quality of patient and site management, clinical supplies, drug accountability and patient-generated data in their clinical development efforts. YPrime’s configurable and customizable IRT and eCOA platforms enable greater speed, precision and integration in clinical trial management. The company’s data services tools eliminate data silos and help sponsors bring together fragmented clinical research data into contextual and actionable information. For more information, visit https://www.yprime.com/.
263 Great Valley Parkway
Malvern, PA 19355
Contact: Katherine Cloninger
While translation and cultural adaptation are time-intensive and require domain expertise, there are emerging best practices that not only save time, but also eliminate unnecessary work and reduce risk of error and timeline delays. his webinar will discuss the process of translation and cultural adaptation to support eCOA implementation on a global scale.
“Configurable” and “customizable” are two commonly-used descriptors for interactive response technology systems that support clinical trials. Interpretations of these terms can vary widely. This webinar discusses definitions and system functionality in the context of configurable and customizable and includes systems development life cycle (SDLC) methodologies, the impact on timelines and cost and common applications in interactive response technology system designs.
Bryan Clayton, Vice President, Strategic Solutions, YPrime recently presented a webinar on IRT technology. This article recaps the discussion on IRT terminology, SDLC methodologies and how different approaches can save time, risk and cost.
Wearables and mobile devices are the tools behind a new kind of clinical trial. Read how when they are paired with complementary technology like eCOA, IRT and other eClinical systems it can drive patient-centric studies that also benefit sponsors and investigator sites.
For biopharmaceutical sponsors, clinical trial data are both the greatest organizational asset and the greatest challenge. This paper discusses the principles of data governance and how they are used to build a business intelligence framework that advances data quality, acquisition, and integration to deliver actionable information for use across the drug development enterprise.
Recently, nearly 2000 participants attended the 10th Annual Scope Meeting. Read the expert perspectives, insights gained from lessons learned and forward-looking predictions across 10 parallel tracks focused on functional areas and emerging disciplines within clinical development.